Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.26 USD | -3.28% | -3.17% | -9.26% |
May. 23 | Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study | MT |
May. 23 | Transcript : Supernus Pharmaceuticals, Inc. - Special Call |
Business Summary
Number of employees: 652
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Treatment of Central Nervous System Diseases
100.0
%
| 667 | 100.0 % | 608 | 100.0 % | -8.95% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 667 | 100.0 % | 608 | 100.0 % | -8.95% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jack Khattar
FOU | Founder | 62 | 05-03-29 |
Timothy Dec
DFI | Director of Finance/CFO | 65 | 21-08-22 |
Frank Mottola
CTO | Chief Tech/Sci/R&D Officer | 52 | 04-12-31 |
Jonathan Rubin
CTO | Chief Tech/Sci/R&D Officer | 62 | 20-01-31 |
Chief Tech/Sci/R&D Officer | 66 | 05-03-29 | |
Compliance Officer | 61 | 11-12-31 | |
Taylor Raiford
SAM | Sales & Marketing | - | 14-12-31 |
Todd Horich
SAM | Sales & Marketing | - | 18-05-30 |
Corporate Officer/Principal | - | 15-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Georges Gemayel
BRD | Director/Board Member | 63 | 15-03-22 |
Charles Newhall
CHM | Chairman | 78 | 05-03-29 |
John Siebert
BRD | Director/Board Member | 84 | 10-12-31 |
Frederick Hudson
BRD | Director/Board Member | 78 | 10-11-15 |
Carrolee Barlow
BRD | Director/Board Member | 60 | 18-06-26 |
Jack Khattar
FOU | Founder | 62 | 05-03-29 |
Bethany Sensenig
BRD | Director/Board Member | 48 | 23-08-20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 54,974,254 | 52,214,537 ( 94.98 %) | 0 | 94.98 % |
Company contact information
Supernus Pharmaceuticals, Inc.
9715 Key West Avenue
20850, Rockville
+301 838 2500
http://www.supernus.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.26% | 1.44B | |
+18.88% | 80.5B | |
+15.17% | 9.15B | |
-14.14% | 4.9B | |
+43.39% | 4.49B | |
+18.90% | 4.44B | |
+7.93% | 2.19B | |
-28.40% | 2.13B | |
+15.93% | 2.1B | |
-43.17% | 1.78B |
- Stock Market
- Equities
- SUPN Stock
- Company Supernus Pharmaceuticals, Inc.